![](/images/graphics-bg.png)
Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
Joint Authors
Yamamoto, Yutaka
Akashi, Yasunori
Minami, Takahumi
Nozawa, Masahiro
Kiba, Keisuke
Yoshikawa, Motokiyo
Hirayama, Akihide
Uemura, Hirotsugu
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-09-16
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Introduction.
The treatment strategy for castration-resistant prostate cancer (CRPC) has changed with the approval of several new agents.
In 2011, abiraterone acetate was approved for the treatment of metastatic CRPC; however abiraterone is known to cause mineralocorticoid excess syndrome characterized by hypokalemia, fluid retention, and hypertension.
We experienced two cases of grade 4 hypokalemia associated with abiraterone treatment.
Case Presentation.
Case 1: a 71-year-old male with metastatic CRPC presented with convulsive seizures two weeks after receiving abiraterone plus prednisone.
The serum potassium level was 2.1mEq/l.
We determined that convulsive seizure was caused by hypokalemia associated with abiraterone.
Case 2: a 68-year-old male with metastatic CRPC presented with severe lethargy one month after receiving abiraterone plus prednisone.
The serum potassium level was 1.7mEq/l and we concluded that severe lethargy was caused by hypokalemia associated with abiraterone.
They were treated with potassium supplementation and increased prednisone following withdrawal of abiraterone.
Discussion.
The two patients had been on glucocorticoid therapy before abiraterone therapy.
Prolonged administration of exogenous glucocorticoid can lead adrenocortical insufficiency and consequently reduce endogenous glucocorticoid production.
This situation may increase the risk of abiraterone-induced mineralocorticoid excess.
To reduce the risk of abiraterone-induced hypokalemia, evaluation of adrenocortical insufficiency is required.
American Psychological Association (APA)
Yamamoto, Yutaka& Akashi, Yasunori& Minami, Takahumi& Nozawa, Masahiro& Kiba, Keisuke& Yoshikawa, Motokiyo…[et al.]. 2018. Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer. Case Reports in Urology،Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1151300
Modern Language Association (MLA)
Yamamoto, Yutaka…[et al.]. Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer. Case Reports in Urology No. 2018 (2018), pp.1-6.
https://search.emarefa.net/detail/BIM-1151300
American Medical Association (AMA)
Yamamoto, Yutaka& Akashi, Yasunori& Minami, Takahumi& Nozawa, Masahiro& Kiba, Keisuke& Yoshikawa, Motokiyo…[et al.]. Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer. Case Reports in Urology. 2018. Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1151300
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1151300